title: Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats.
abstract: The nucleolus, the site of ribosomal ribonucleic acid (rRNA) transcription and assembly, is an important player in the cellular response to stress. Altered nucleolar function and morphology, including decreased nucleolar volume, has been observed in Parkinson's disease; thus the nucleolus represents a potential indicator of neurodegeneration in the disease. This study determined the effects of a partial unilateral intrastriatal 6-hydroxydopamine (6-OHDA) lesion, which models the dopaminergic loss found in Parkinson's disease, on the nucleoli of dopaminergic cells in the substantia nigra pars compacta (SNpc). Adult male Long-Evans rats underwent unilateral intrastriatal infusion of 6-OHDA (12.5μg). Lesions were verified by amphetamine-stimulated rotation 7 days later, and rats were euthanized 14 days after infusion. Coronal sections (50μm) were stained for tyrosine hydroxylase-silver nucleolar (TH-AgNOR) stain using MultiBrain Technology (NeuroScience Associates), which resulted in clearly defined nucleoli and neuronal outlines. Stereological methods were used to compare dopaminergic morphology between lesioned and intact hemispheres in each rat. In cells exhibiting a definable nucleolus, nucleolar volume was decreased by 16% on the ipsilateral side. The ipsilateral SNpc also exhibited an 18% decrease in SNpc planimetric volume, a 46% decrease in total TH-positive neuron number, and an 11% decrease in neuronal body volume (all P<0.05 by paired t-test). These findings suggest that the 6-OHDA lesion alters nucleolar morphology and that these changes are similar to those occurring in Parkinson's disease.
authors: Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA. mstoffel@kumc.edu
authors: Michelle
authors: M
authors: Healy-Stoffel
authors: S Omar
authors: SO
authors: Ahmad
authors: John A
authors: JA
authors: Stanford
authors: Beth
authors: B
authors: Levant
mesh_terms: D000818:Animals; D002466:Cell Nucleolus / Q000187:drug effects / Q000473:pathology*; D002478:Cells, Cultured; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000473:pathology*; D008297:Male; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000473:pathology*; D051381:Rats; D020318:Rats, Long-Evans; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology*
chemical_list: D016627:Oxidopamine
references: Trends Neurosci. 2012 May;35(5):305-14
references: 22305768
references: Mol Cell. 2005 Jul 1;19(1):77-87
references: 15989966
references: J Microsc. 1999 Mar;193(Pt 3):199-211
references: 10348656
references: J Neuropathol Exp Neurol. 2008 Jun;67(6):578-89
references: 18520776
references: J Neurosci. 2011 Jan 12;31(2):453-60
references: 21228155
references: Acta Neuropathol. 2008 Apr;115(4):461-70
references: 18297291
references: Neuroscience. 2005;130(4):813-31
references: 15652981
references: Exp Neurol. 1998 Aug;152(2):259-77
references: 9710526
references: Pharmacol Rev. 1974 Sep;26(3):199-288
references: 4376244
references: Neuroscience. 1996 Jun;72(3):641-53
references: 9157311
references: Pharmacol Biochem Behav. 2010 Oct;96(4):423-8
references: 20600242
references: Cell Mol Life Sci. 2010 Jun;67(11):1817-29
references: 20148281
references: Lancet. 1990 Apr 21;335(8695):948-52
references: 1691427
references: Mol Cell. 2010 Oct 22;40(2):216-27
references: 20965417
references: Exp Neurol. 2002 Jun;175(2):303-17
references: 12061862
references: J Neural Transm Suppl. 2009;(73):203-13
references: 20411779
references: Exp Neurol. 2001 Oct;171(2):405-17
references: 11573992
references: J Neurochem. 2011 Jun;117(6):1033-46
references: 21517844
references: J Pharmacol Exp Ther. 1978 Nov;207(2):544-54
references: 712637
references: J Neurosci Methods. 2012 Sep 30;210(2):187-94
references: 22850559
references: Neurosci Lett. 1998 Feb 13;242(2):69-72
references: 9533396
references: Int J Neurosci. 2005 Apr;115(4):557-82
references: 15804725
references: Arch Neurol. 1982 Sep;39(9):545-9
references: 7115143
references: J Neural Transm Suppl. 1997;50:55-66
references: 9120425
references: Neuroscience. 2000;97(1):99-112
references: 10877666
references: Neurosci Lett. 2008 Jun 27;438(3):303-7
references: 18499349